RBC Capital Reiterates Buy Rating for Edwards Lifesciences

RBC Capital reiterated its 'buy' rating on Edwards Lifesciences Corporation (NYSE:EW) on June 16, 2026. Analyst Shagun Singh set a price target of $100, indicating confidence in the company's future prospects.

Other Institutional Activity in Edwards Lifesciences

BlackRock, Inc. grew its holdings by 129,018 shares, ending with 52,590,933 shares worth about $4.21 billion. Vanguard Capital Management LLC added a significant 37,727,792 shares, reaching a total of 37,727,792 shares valued at approximately $3.02 billion. Similarly, Vanguard Portfolio Management LLC increased its position by 26,407,018 shares, totaling 26,407,018 shares valued at about $2.11 billion. State Street Corp added 304,875 shares, bringing its holdings to 26,296,399 shares worth around $2.11 billion. Wellington Management Group LLP also increased its stake by 217,152 shares, totaling 22,011,101 shares valued at $1.76 billion.

Edwards Lifesciences Stock Snapshot

Shares of Edwards Lifesciences (NYSE:EW) are trading at $86.28. The company has a market cap of $49.68 billion and a P/E ratio of 46.64. Its forward P/E is 25.62, and the stock has a beta of 0.866. The 52-week range is between $72.30 and $89.48, with a 50-day moving average of $82.88 and a 200-day moving average of $81.87. The company maintains a strong balance sheet with a current ratio of 4.42 and a quick ratio of 3.30, alongside a debt-to-equity ratio of 6.81.

Recent Earnings

For the latest earnings period, Edwards Lifesciences reported revenue of $6.30 billion, reflecting a growth rate of 16.7%. The company achieved a net margin of 17.39% and a return on equity of 10.46%. Earnings per share came in at $1.85. The next earnings report is expected on July 23, 2026.

Insider Buying and Selling at Edwards Lifesciences Corporation

Recent insider activity at Edwards Lifesciences included several transactions. On May 29, 2026, Andrew Dahl, SVP and Corporate Controller, sold 568 shares at an average price of $86.08. Donald Bobo Jr., CVP of Strategy and Corporate Development, sold 23,145 shares on May 27, 2026, at $86.42 per share. On May 22, 2026, Daveen Chopra, CVP of TMTT & Surgical, sold 1,500 shares at $84.60. Daniel Lippis, CVP of TAVR, made multiple transactions on May 18, 2026, including buying 620 shares at $72.68.

Analysts Set New Price Targets

On June 16, 2026, RBC Capital reiterated its 'buy' rating with a $100 price target. TD Cowen maintained a 'buy' rating with a $104 target on June 2, 2026. Barclays also maintained a 'buy' rating, setting a high target of $110 on April 27, 2026. Overall, the consensus among 26 analysts is a 'buy' rating, with an average target price of $96.92.

About Edwards Lifesciences

Edwards Lifesciences Corporation, based in Irvine, California, is a leading provider of medical devices, particularly those used in treating cardiovascular diseases. The company offers innovative products such as transcatheter heart valves and surgical valve solutions. Led by CEO Bernard J. Zovighian, Edwards Lifesciences employs approximately 16,000 people worldwide and operates in various regions, including the United States, Europe, and Japan.

Bottom Line

RBC Capital's reiteration of a 'buy' rating with a $100 price target reflects confidence in Edwards Lifesciences' potential. The company's solid market position in cardiovascular medical devices, coupled with strong financials and strategic insider moves, continues to attract investor interest. As always, 13F filings and analyst reports are backward-looking and may not reflect the most current investment positions.